Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates

Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes

(2015) Lawrence Blonde et al.   Cardiovascular Diabetology

Glucagon increases energy expenditure independently of brown adipose tissue activation in humans

(2015) V. Salem et al.   DIABETES OBESITY & METABOLISM

Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure

(2015) Jonatan Ising Bagger et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Incretin-based therapies for obesity treatment

(2015) Aline Haas de Mello et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

(2015) Xavier Pi-Sunyer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

(2015) Annachiara Uccellatore et al.   Diabetes Therapy

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

(2015) Annachiara Uccellatore et al.   Diabetes Therapy

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis

(2015) Jessica E. Potts et al.   PLoS One

Glucagon Regulates Hepatic Kisspeptin to Impair Insulin Secretion

(2014) Woo-Jin Song et al.   Cell Metabolism

Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake

(2014) Jaimini Cegla et al.   DIABETES

Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes

(2014) Michaela Diamant et al.   DIABETES CARE

Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)

(2014) Helena M. de Wit et al.   DIABETOLOGIA

Metastasis Suppressor KISS1 Seems to Reverse the Warburg Effect by Enhancing Mitochondrial Biogenesis

(2013) W. Liu et al.   CANCER RESEARCH

GLP-1 Receptor Agonists: Effects on Cardiovascular Risk Reduction

(2013) Daniel Lorber   Cardiovascular Therapeutics

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action

(2013) Jonathan E. Campbell et al.   Cell Metabolism

Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions

(2013) K. M. Habegger et al.   DIABETES

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

(2013) J van Can et al.   INTERNATIONAL JOURNAL OF OBESITY

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

(2013) T A Wadden et al.   INTERNATIONAL JOURNAL OF OBESITY

Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents

(2012) Jonathan W. Day et al.   BIOPOLYMERS

Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia

(2012) T. M. Tan et al.   DIABETES

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas

(2012) M. Davies et al.   DIABETES CARE

Unraveling oxyntomodulin, GLP1's enigmatic brother

(2012) Alessandro Pocai   JOURNAL OF ENDOCRINOLOGY

The metabolic actions of glucagon revisited

(2010) Kirk M. Habegger et al.   Nature Reviews Endocrinology

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

(2009) A. Pocai et al.   DIABETES

A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year prospective randomized intervention study

(2009) A. Elhayany et al.   DIABETES OBESITY & METABOLISM

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

(2009) Jonathan W Day et al.   Nature Chemical Biology